Artiva Biotherapeutics receives multiple "Buy" ratings from analysts with target prices between $18-$23.

Artiva Biotherapeutics (NASDAQ: ARTV), a clinical-stage biotech firm developing natural killer (NK) cell therapies for autoimmune diseases and cancers, has received multiple "Buy" ratings from analysts, including Needham & Company, which set a target price of $23.00. Other firms like Wedbush, TD Cowen, and Jefferies also issued buy ratings with targets between $18.00 and $23.00. The company's lead candidate, AB-101, targets several serious conditions.